Naproxen
- Product NDC
- 25000-138
- Requested package NDC
- 25000-138-21
- 11-digit product format
- 250000138
- Labeler code
- 25000
- Product ID
- 25000-138_e5013319-e2f4-4cd0-9523-1ffd352fe2d9
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Naproxen
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- MARKSANS PHARMA LIMITED
- Application
- ANDA091416
- Marketing category
- ANDA
- Marketing start
- 2011-02-28
- Substance
- NAPROXEN
- Active strength
- 250 mg/1
- Pharmacologic classes
- Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091416-001 | NAPROXEN | NAPROXEN | 250MG | TABLET / ORAL | AB | 2011-02-14 | |
| A091416-002 | NAPROXEN | NAPROXEN | 375MG | TABLET / ORAL | AB | 2011-02-14 | |
| A091416-003 | NAPROXEN | NAPROXEN | 500MG | TABLET / ORAL | AB | 2011-02-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A091416-001 | AB |
| A091416-002 | AB |
| A091416-003 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091416-001 | NAPROXEN | 250MG | TABLET / ORAL | AB | 2011-02-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A091416-002 | NAPROXEN | 375MG | TABLET / ORAL | AB | 2011-02-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A091416-003 | NAPROXEN | 500MG | TABLET / ORAL | AB | 2011-02-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091416-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A091416-002 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A091416-003 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| NAPROXEN | NAPROXEN | Northwind Health Company, LLC | f32d755e-4984-ee40-e053-2995a90a4ebe | 2026-01-01 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | QPharma Inc | c0a4839b-7154-c82c-e053-2a95a90a7e6d | 2025-12-03 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | PD-Rx Pharmaceuticals, Inc. | a9f9ce81-9d51-4167-9581-974866a8fe31 | 2025-10-17 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | DIRECT RX | b1b78c49-82e9-2402-e053-2a95a90ae35f | 2025-01-17 | Warnings | 091416 ANDA091416 |
| Naproxen | NAPROXEN | Advanced Rx of Tennessee, LLC | af9a96cf-1cda-8ace-e053-2a95a90a18cc | 2024-12-31 | Boxed warning, Warnings, Adverse reactions | 091416 ANDA091416 |
| Naproxen | NAPROXEN | MARKSANS PHARMA LIMITED | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 2024-12-02 | Boxed warning, Warnings, Adverse reactions | 091416 ANDA091416 25000-138-21 25000-138 25000013821 |
| NAPROXEN | NAPROXEN | NuCare Pharmaceuticals,Inc. | 5487dee2-5c37-4348-e054-00144ff8d46c | 2024-07-17 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | NuCare Pharmaceuticals,Inc. | 71d4a048-ca50-73db-e053-2a95a90ad465 | 2024-06-10 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | NuCare Pharmaceuticals,Inc. | 69366b55-2687-17a4-e053-2a91aa0a65b3 | 2024-06-07 | 091416 ANDA091416 | |
| NAPROXEN | NAPROXEN | Asclemed USA, Inc. | a4fcb411-c918-459b-adc6-06dfa8ed8a50 | 2022-10-12 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | Aphena Pharma Solutions - Tennessee, LLC | 32693390-763b-46dd-b821-65a7bf3c6671 | 2021-04-26 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | Bryant Ranch Prepack | 5d399bf3-db49-411a-91b9-b410d702a65a | 2020-12-14 | Warnings | 091416 ANDA091416 |
| NAPROXEN | NAPROXEN | TIME CAP LABORATORIES | 4350a2d9-5228-460e-b7b1-27e8fa846787 | 2018-10-09 | Warnings | 091416 ANDA091416 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Naproxen
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| NAPROXEN | 250 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 57Y76R9ATQ | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fef6ad89-235f-4274-ba49-a8e53642473e | Product name | 2 | 20250225 |
| 87fed3e6-8fba-48ef-96b0-3a7fb54b96ff | Product name | 3 | 20230306 |
| b5fdaaec-7251-4da6-9cb2-4e9e76939ec8 | Product name | 1 | 20200623 |
| e76dbbc1-775d-722c-08ff-ed45e8a80def | Product name | 3 | 20181002 |
| 6f4f4521-fd56-1ae6-888b-3b021bd75c7c | Product name | 1 | 20140508 |
| ce67e27d-1d21-5465-4409-b0662dd99d4d | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 25000-138-03 | Naproxen | 30 in 1 BOTTLE | TABLET | 30 | 14 | |
| 25000-138-14 | Naproxen | 1000 in 1 BOTTLE | TABLET | 1000 | 14 | |
| 25000-138-21 | Naproxen | 7500 in 1 BAG | TABLET | 7500 | 14 | |
| 25000-138-21 | Naproxen | 4 in 1 BOX | TABLET | 4 | 14 | |
| 25000-138-31 | Naproxen | 6 in 1 BOX | TABLET | 6 | 14 | |
| 25000-138-31 | Naproxen | 7500 in 1 BAG | TABLET | 7500 | 14 | |
| 25000-138-98 | Naproxen | 37950 in 1 BAG | TABLET | 37950 | 14 | |
| 25000-138-98 | Naproxen | 1 in 1 BOX | TABLET | 1 | 14 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| NAPROXEN | ACTIVE INGREDIENT | 57Y76R9ATQ | NAPROXEN TABLET [MARKSANS PHARMA LIMITED] | 4 | |
| NAPROXEN | ACTIVE MOIETY | 57Y76R9ATQ | NAPROXEN TABLET [MARKSANS PHARMA LIMITED] | 4 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | NAPROXEN TABLET [MARKSANS PHARMA LIMITED] | 4 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | NAPROXEN TABLET [MARKSANS PHARMA LIMITED] | 4 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | NAPROXEN TABLET [MARKSANS PHARMA LIMITED] | 4 |
DailyMed Dashboard NDC Coverage#
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 198013 | naproxen 250 MG Oral Tablet | PSN | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
| 198012 | naproxen 375 MG Oral Tablet | PSN | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
| 198014 | naproxen 500 MG Oral Tablet | PSN | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
| 198013 | naproxen 250 MG Oral Tablet | SCD | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
| 198012 | naproxen 375 MG Oral Tablet | SCD | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
| 198014 | naproxen 500 MG Oral Tablet | SCD | 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 | 14 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 25000-138-21 | 25000013821 | 4 BAG in 1 BOX (25000-138-21) / 7500 TABLET in 1 BAG | 4 bag | 2011-02-28 | 0000-00-00 | No | No | Current |